View Older Stories View More Recent Stories

Jan 4, 2021 06:58AM Myovant Sciences Appoints Industry Veteran David Marek as Chief Executive Officer
Dec 28, 2020 09:37AM UPDATE - Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
Dec 28, 2020 06:55AM Sumitovant Biopharma Announces Myovant Sciences and Pfizer Enter Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
Dec 28, 2020 06:31AM Myovant Sciences (MYOV) Enters Collaboration with Pfizer (PFE) to Develop and Commercialize Relugolix; to Receive $650M Upfront
Dec 28, 2020 06:30AM Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
Dec 28, 2020 06:30AM Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
Dec 18, 2020 04:49PM Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
Dec 18, 2020 04:49PM Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
Dec 16, 2020 08:30AM Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Nov 23, 2020 07:00AM Myovant Sciences to Present at Upcoming December Investor Conferences
Nov 17, 2020 08:30AM Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
Nov 12, 2020 07:00AM Myovant Sciences Announces Corporate Updates and Financial Results for Second Quarter Fiscal Year 2020
Nov 2, 2020 08:30AM Myovant Sciences to Host Second Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on November 12, 2020
Nov 2, 2020 08:30AM Myovant Sciences to Host Second Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on November 12, 2020
Oct 21, 2020 08:30AM Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids
Oct 21, 2020 08:30AM Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Studies in Endometriosis and Uterine Fibroids
Oct 14, 2020 08:30AM Myovant Sciences Appoints Ryan Crowe as Vice President, Investor Relations
Oct 14, 2020 08:30AM Myovant Sciences Appoints Ryan Crowe as Vice President, Investor Relations
Sep 29, 2020 08:33AM Myovant Sciences (MYOV) Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer
Sep 29, 2020 08:30AM Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer
Sep 29, 2020 08:30AM Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer
Sep 23, 2020 08:30AM Myovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
Sep 23, 2020 08:30AM Myovant Sciences Launches “Forward for Health Equity” Grant Program to Improve Healthcare Access in Prostate Cancer and Uterine Fibroids
Sep 14, 2020 08:33AM Myovant Sciences (MYOV) Highlights Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 LIBERTY Program & from Prospective Observational Study
Sep 14, 2020 08:30AM Myovant Sciences Presents Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 LIBERTY Program and from Prospective Observational Study
Sep 14, 2020 08:30AM Myovant Sciences Presents Additional Data on Bone Mineral Density in Women with Uterine Fibroids from Phase 3 LIBERTY Program and from Prospective Observational Study
Aug 17, 2020 08:33AM Myovant Sciences (MYOV) Reports FDA Acceptance of NDA for Once-Daily Relugolix Combination Tablet for Uterine Fibroids
Aug 17, 2020 08:30AM Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids
Aug 17, 2020 08:30AM Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids
Aug 11, 2020 08:30AM Myovant Sciences Announces Corporate Updates and Financial Results for First Quarter Fiscal Year 2020
Aug 5, 2020 08:30AM Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion Pharmaceuticals
Aug 5, 2020 08:30AM Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion Pharmaceuticals
Jul 6, 2020 08:31AM Myovant Sciences (MYOV) Reports Additional Data on Relugolix Combination Therapy from Phase 3 LIBERTY
Jul 6, 2020 08:30AM Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Phase 3 LIBERTY Studies in Women with Uterine Fibroids and from Ovulation Inhibition Study
Jul 6, 2020 08:30AM Myovant Sciences Presents Additional Data on Relugolix Combination Therapy from Phase 3 LIBERTY Studies in Women with Uterine Fibroids and from Ovulation Inhibition Study
Jun 30, 2020 08:30AM BlackDoctor.org, Evidation Health, Movember, and Myovant Sciences Launch Forward Momentum Coalition to Increase Diversity in Research and Develop New Digital Resources for Men with Prostate Cancer
Jun 23, 2020 07:31AM Myovant Sciences (MYOV) Reports Positive Results from Second Ph. 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Jun 23, 2020 07:30AM Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Jun 23, 2020 07:30AM Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis
Jun 22, 2020 10:14PM Sumitovant Biopharma Announces Priority Review and FDA Acceptance of Myovant Sciences New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer
Jun 22, 2020 04:05PM Myovant Sciences to Host Webcast and Conference Call at 8:30 am Eastern Time Tuesday, June 23 to Discuss Results from Phase 3 SPIRIT 1 Study Evaluating Once-Daily Relugolix Combination Therapy in Wome
Jun 22, 2020 04:05PM Myovant Sciences to Host Webcast and Conference Call at 8:30 am Eastern Time Tuesday, June 23 to Discuss Results from Phase 3 SPIRIT 1 Study Evaluating Once-Daily Relugolix Combination Therapy in Wome
Jun 22, 2020 08:32AM Myovant Sciences (MYOV) Announces Priority Review and FDA Acceptance of NDA for Once-Daily, Oral Relugolix for Advanced Prostate Cancer
Jun 22, 2020 08:30AM Myovant Sciences Announces Priority Review and FDA Acceptance of New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer
Jun 22, 2020 08:30AM Myovant Sciences Announces Priority Review and FDA Acceptance of New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer
Jun 1, 2020 05:11PM Sumitovant Biopharma Announces Myovant Sciences' Submission of New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
Jun 1, 2020 08:02AM Myovant Sciences (MYOV) Submits NDA to FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
Jun 1, 2020 08:00AM Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
Jun 1, 2020 08:00AM Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
May 29, 2020 05:00PM Sumitovant Biopharma Announces Myovant Sciences' Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publi
View More Recent Stories View Older Stories